Cargando…

Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy

BACKGROUND: The efficacy of dendritic cell (DC) immunotherapy as a single therapeutic modality for the treatment of glioblastoma (GBM) patients remains limited. In this study, we evaluated in patients with GBM recurrence the immune-mediated effects of DC loaded with autologous tumor lysate combined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eoli, Marica, Corbetta, Cristina, Anghileri, Elena, Di Ianni, Natalia, Milani, Micaela, Cuccarini, Valeria, Musio, Silvia, Paterra, Rosina, Frigerio, Simona, Nava, Sara, Lisini, Daniela, Pessina, Sara, Maddaloni, Luisa, Lombardi, Raffaella, Tardini, Maria, Ferroli, Paolo, DiMeco, Francesco, Bruzzone, Maria Grazia, Antozzi, Carlo, Pollo, Bianca, Finocchiaro, Gaetano, Pellegatta, Serena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212883/ https://www.ncbi.nlm.nih.gov/pubmed/32642658 http://dx.doi.org/10.1093/noajnl/vdz022

Ejemplares similares

Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide
por: Pellegatta, Serena, et al.
Publicado: (2018)

ABCC3 Expressed by CD56(dim) CD16(+) NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy
por: Pellegatta, Serena, et al.
Publicado: (2019)

P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses
por: Pellegatta, S, et al.
Publicado: (2014)

The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
por: Pellegatta, Serena, et al.
Publicado: (2013)

Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches
por: Anghileri, Elena, et al.
Publicado: (2021)

Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment against Glioblastoma
por: Cuccarini, Valeria, et al.
Publicado: (2019)

CLRM-08 TARGETING IMMUNE-PAYLOAD TO THE GLIOBLASTOMA TUMOR MICROENVIRONMENT USING A MACROPHAGE-BASED TREATMENT RELYING ON AUTOLOGOUS, GENETICALLY MODIFIED, HEMATOPOIETIC STEM CELL-BASED THERAPY: THE TEM-GBM STUDY (NCT03866109)
por: Eoli, Marica, et al.
Publicado: (2022)

Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma
por: Di Ianni, Natalia, et al.
Publicado: (2021)

Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan
por: Aquino, Domenico, et al.
Publicado: (2014)

Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
por: Cuppini, Lucia, et al.
Publicado: (2013)

P1359: USING GENE-MODIFIED AUTOLOGOUS STEM CELLS PROGENY TO REEDUCATE THE TUMOR IMMUNE MICROENVIRONMENT OF SOLID TUMORS (TEM-GBM STUDY)
por: Farina, F., et al.
Publicado: (2022)

An Optimized Method for Manufacturing a Clinical Scale Dendritic Cell-Based Vaccine for the Treatment of Glioblastoma
por: Nava, Sara, et al.
Publicado: (2012)

The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma
por: Pessina, Sara, et al.
Publicado: (2015)

Sporadic spinal psammomatous malignant melanotic nerve sheath tumor: A case report and literature review
por: Bonomo, Giulio, et al.
Publicado: (2023)

Case report: Multiple brain intravascular papillary endothelial hyperplasia: incidence, diagnostic challenges, and management approach
por: Anghileri, Elena, et al.
Publicado: (2023)

Characterization of 22q12 Microdeletions Causing Position Effect in Rare NF2 Patients with Complex Phenotypes
por: Tritto, Viviana, et al.
Publicado: (2022)

Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction
por: Di Ianni, Natalia, et al.
Publicado: (2021)

Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres
por: Patanè, Monica, et al.
Publicado: (2013)

PGE(2) Is Crucial for the Generation of FAST Whole- Tumor-Antigens Loaded Dendritic Cells Suitable for Immunotherapy in Glioblastoma
por: Nava, Sara, et al.
Publicado: (2020)

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
por: Pellegatta, Serena, et al.
Publicado: (2015)

Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients
por: Bianchessi, Donatella, et al.
Publicado: (2020)

NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma
por: Speranza, Maria Carmela, et al.
Publicado: (2012)

Ex Vivo Fluorescein-Assisted Confocal Laser Endomicroscopy (CONVIVO® System) in Patients With Glioblastoma: Results From a Prospective Study
por: Acerbi, Francesco, et al.
Publicado: (2020)

Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity
por: Cantini, Gabriele, et al.
Publicado: (2012)

MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives
por: Aquino, Domenico, et al.
Publicado: (2017)

Cognitive and Behavioral Outcome of Pediatric Low-Grade Central Nervous System Tumors Treated Only with Surgery: A Single Center Experience
por: Taddei, Matilde, et al.
Publicado: (2023)

Tumor-initiating cell frequency is relevant for glioblastoma aggressiveness
por: Richichi, Cristina, et al.
Publicado: (2016)

Towards an Established Intraoperative Oncological Favorable Tool: Results of Fluorescein-Guided Resection from a Monocentric, Prospective Series of 93 Primary Glioblastoma Patients
por: Falco, Jacopo, et al.
Publicado: (2022)

May we deliver neuro-oncology in difficult times (e.g. COVID-19)?
por: Perin, Alessandro, et al.
Publicado: (2020)

B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres
por: Nehama, Dean, et al.
Publicado: (2019)

Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
por: Nava, Sara, et al.
Publicado: (2021)

Image guidance in skull base tumor resection: A synergistic approach using intraoperative navigated angiosonography for real-time vessel visualization
por: Prada, Francesco, et al.
Publicado: (2016)

Editorial: Intraoperative Ultrasound in Brain Tumor Surgery: State-Of-The-Art and Future Perspectives
por: Del Bene, Massimiliano, et al.
Publicado: (2021)

Current and Future Novel Treatments for Glioblastoma Multiforme
por: Tyler, Betty, et al.
Publicado: (2014)

In Silico Mathematical Modelling for Glioblastoma: A Critical Review and a Patient-Specific Case
por: Falco, Jacopo, et al.
Publicado: (2021)

Sporadic and von Hippel–Lindau Related Hemangioblastomas of Brain and Spinal Cord: Multimodal Imaging for Intraoperative Strategy
por: Mazzapicchi, Elio, et al.
Publicado: (2022)

Editorial. Neurosurgery in the storm of COVID-19: suggestions from the Lombardy region, Italy (ex malo bonum)
por: Cenzato, Marco, et al.
Publicado: (2020)

Diagnostic and surgical management of primary central nervous system angioleiomyoma: A case report and literature review
por: Rubiu, Emanuele, et al.
Publicado: (2022)

126 novel mutations in Italian patients with neurofibromatosis type 1
por: Bianchessi, Donatella, et al.
Publicado: (2015)

Reactivation of COVID-19 in a neurosurgical patient with early neuropsychiatric presentation. Does seroconversion mean immunity?
por: Bonomo, Giulio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eenc9cphkaejpvi17hl1a9m8vf